Biohaven Shares Decline After FDA Places Clinical Hold on Epilepsy Trial

Biohaven Pharmaceuticals (NYSE: BHVN) experienced a significant stock price drop of nearly 15%, or $2.21 per share, on September 10, 2026. The decline followed an announcement that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on new patient enrollment in clinical trials for its epilepsy drug candidate, BHV-7000, also known as opakalim.

The FDA's decision impacts the ongoing trials involving BHV-7000, which is being investigated for its potential to treat epilepsy. While the hold is partial and does not affect existing patients in the trial, it halts the initiation of new participants into the study. The specific reasons for the hold were not immediately detailed by the FDA or Biohaven.

Biohaven's stock closed at $12.81 per share on September 10, reflecting investor concerns over the regulatory setback. This development could delay the drug's progression through the clinical trial phases and potentially impact its future market availability. The company has not yet provided a detailed timeline for addressing the FDA's concerns or the potential lifting of the hold.

This regulatory action comes at a critical juncture for Biohaven's epilepsy program. Investors will be closely monitoring the company's communications regarding the steps it intends to take to resolve the FDA's concerns and resume full trial participation. The outcome of this investigation will be crucial for the future development of BHV-7000.